Cognito Therapeutics' Spectris Device Shows Promise in Modulating Brain Resilience Pathways in Alzheimer's Disease
核心洞察
Cognito Therapeutics (搜索) presented new biomarker data at CTAD 2025 showing that Spectris therapy significantly increased Neuritin-1 (搜索) levels in cerebrospinal fluid, a protein crucial for synaptic plasticity and brain resilience.
The non-invasive at-home device demonstrated coordinated changes in proteins related to immune regulation, oxidative stress, and extracellular matrix remodeling, suggesting broad neuroprotective effects.
EEG analysis from the OVERTURE trial revealed that Spectris treatment reduced progression of Alzheimer's disease (搜索)-related brain wave patterns over six months.
Cognito Therapeutics (搜索) has unveiled compelling new biomarker evidence suggesting its investigational Spectris device may modulate key brain resilience pathways in Alzheimer's disease (搜索) patients. The data, presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, provides biological validation for the non-invasive neurostimulation therapy's previously reported clinical benefits.
CSF Proteomic Analysis Reveals Neuroplasticity Enhancement
In a cerebrospinal fluid (CSF) proteomics analysis from the FLICKER trial, daily Spectris use was associated with a significant increase in Neuritin-1 (搜索) abundance (p< 0.01). This activity-dependent neurotrophic factor plays a central role in experience-driven synaptic remodeling, dendritic stabilization, and synaptic retention—all key elements of brain structural plasticity and maintenance.
The finding carries particular significance given that reduced CSF Neuritin-1 (搜索) abundance has been observed in Alzheimer's patients and correlates with cognitive decline and higher CSF phosphorylated tau (搜索) (p-tau) levels. Neuritin-1 appears as a top-ranked protein in cognitive resilience modules that may distinguish preserved cognition from typical Alzheimer's disease (搜索) trajectories.
Beyond Neuritin-1 (搜索), Spectris produced coordinated changes in the abundance of proteins (all p<0.01) related to immune regulation, oxidative stress, and extracellular matrix remodeling. These findings suggest the therapy may influence several interconnected pathways that support neuroprotection and brain resilience.
EEG Patterns Show Reduced Disease Progression
A second presentation featured resting-state EEG findings from the OVERTURE randomized controlled trial. Over six months of treatment, participants using Spectris demonstrated a reduction in the progression of EEG patterns characteristic of Alzheimer's disease (搜索), including theta/alpha ratio changes. These findings may suggest that Spectris mitigates Alzheimer's disease EEG progression and complement earlier observations of preserved structural and functional measures in treated participants.
Clinical Implications and Mechanism of Action
"The data presented at CTAD strengthen the biological foundation behind Spectris and show that a non-invasive, at-home therapy can engage pathways central to brain resilience and health," said Christian Howell, CEO of Cognito Therapeutics (搜索). "The increase in Neuritin-1 (搜索) and coordinated shifts in proteins related to synaptic stability and neuroprotection give us growing confidence that Spectris may be influencing mechanisms relevant to slowing the progression of Alzheimer's."
The Spectris device uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency (搜索) brain activity. The company's feasibility studies have previously shown the potential for Spectris to preserve cognition, daily function, and slow brain atrophy in patients diagnosed with mild-to-moderate Alzheimer's disease (搜索).
Building on Previous Clinical Evidence
These biomarker findings add meaningful context to previously reported Spectris treatment effects on cognition, daily function, and brain volume. The convergence of molecular, electrophysiological, and clinical evidence strengthens the case for the device's potential as a disease-modifying therapy.
Howell emphasized the accessibility aspect of the treatment: "Combined with our EEG and earlier clinical findings, these results underscore Spectris' potential as an accessible, at-home, disease-modifying therapy."
The late-stage medical device company continues to advance its lead product, Spectris AD, as it seeks to address unmet needs in Alzheimer's disease (搜索) treatment through its novel approach to neuroprotection.